autism risk medication, Johnson & Johnson lawsuit, pharmaceutical accountability
HOLEE SHIZZLES
BREAKING: Internal Records show Johnson & Johnson Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 2018, and doctors were warning J&J as early as 2008
- YOU MAY ALSO LIKE TO WATCH THIS TRENDING STORY ON YOUTUBE. Waverly Hills Hospital's Horror Story: The Most Haunted Room 502
• According to the DCNF report, J&J’s Janssen division (its pharmaceutical… pic.twitter.com/OAAFtlDRKG
— MJTruthUltra (@MJTruthUltra) September 26, 2025
HOLEE SHIZZLES
BREAKING: Internal Records show Johnson & Johnson Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 2018
Recent reports have unveiled startling information about Johnson & Johnson (J&J), the maker of Tylenol. Internal records indicate that as early as 2018, the company acknowledged mounting evidence linking their product to an increased autism risk. This revelation raises significant concerns for parents and healthcare providers alike.
Doctors were reportedly warning J&J about potential risks associated with Tylenol as far back as 2008. This long history of warnings suggests a troubling pattern of negligence when it comes to the safety of their products. The implications of these findings are profound, especially for families relying on Tylenol for pain relief during pregnancy or early childhood.
According to the DCNF report, J&J’s Janssen division, which manages its pharmaceutical operations, had access to vital research that could have influenced their marketing and safety practices. The private admissions made by J&J raise critical questions about transparency and accountability in the pharmaceutical industry.
As a concerned consumer or parent, it’s essential to stay informed about the potential risks associated with medications like Tylenol. Understanding the implications of these internal admissions can help you make better health choices for you and your family.
If you want to explore more about this developing story, check out the full report by DCNF. It’s crucial to engage with this ongoing conversation about medication safety and its impact on public health.
Stay tuned for further updates as more information becomes available about Johnson & Johnson’s handling of this significant health concern.